招生          学生培养           合作伙伴      
  •   Chimeric antigen receptor (CAR)-expressing T cells for cancer immunotherapy (Adapted from Heczey A. et al., 2013, Discov Med and Kochenderfer JN. et al., 2013, Nat. Rev. Clin. Oncol)

  •   Cytotoxicity of AC133-specific CAR T cells in vitro

  •   The interaction between glioma cells and CD8+ T cells


T细胞工程实验室
   实验室简介实验室成员发表论文新闻招聘信息

Research Interests


Recent clinical trials have shown that T cell therapy, which makes use of the host's own immune system, can “cure” some cancer patients, such as CD19-specific chimeric antigen receptor (CAR) redirected T cell therapy for B-cell malignancies, adoptive transfer of tumor infiltrating lymphocytes (TILs) for melanoma, cholangiocarcinoma and cervical cancer. However, only a small population of patients now can benefit from this kind of immunotherapy. Our lab is interested in developing engineered tumor-specific T cells for treating more cancer patients.


Current projects include:
1:Targeting cancer stem cells (CSCs) by CAR T cells for the treatment of cancer patients.
2:Combination of CRISPR/cas9 system and CAR technology for producing activated tumor-specific CAR T cells.






 
地址
|

上海张江高科技园区海科路99号6号楼 邮编:201210 
邮箱: siais@shanghaitech.edu.cn

 

Copyright © 2015 上海科技大学免疫化学研究所 版权所有